Vanda Pharmaceuticals Inc. (VNDA) stock
VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3055% below fair value
$3.75−0.06 (-1.57%)
Close on Nov 18, 2026Market cap $226.76MP/E –Yield –
Vanda Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Vanda Pharmaceuticals's total assets was $382.33M at Sep 30, 2026. For fiscal 2025 it was $488.95M, down 25.5% from the year before. Over ten years it grew 8.7% a year on average. The highest annual figure on record is $656.20M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $488.95M | -25.5% |
| FY2024 | Dec 31, 2024 | $656.20M | +1.2% |
| FY2023 | Dec 31, 2023 | $648.44M | +2.2% |
| FY2022 | Dec 31, 2022 | $634.25M | +6.8% |
| FY2021 | Dec 31, 2021 | $593.79M | +11.3% |
| FY2020 | Dec 31, 2020 | $533.46M | +10.3% |
| FY2019 | Dec 31, 2019 | $483.75M | +45.7% |
| FY2018 | Dec 31, 2018 | $332.13M | +61.7% |
| FY2017 | Dec 31, 2017 | $205.43M | -2.4% |
| FY2016 | Dec 31, 2016 | $210.37M | -1.3% |
| FY2015 | Dec 31, 2015 | $213.05M | +24.1% |
| FY2014 | Dec 31, 2014 | $171.70M | +19.8% |
| FY2013 | Dec 31, 2013 | $143.35M | +5.8% |
| FY2012 | Dec 31, 2012 | $135.45M | -25.8% |
| FY2011 | Dec 31, 2011 | $182.62M | -14.3% |
| FY2010 | Dec 31, 2010 | $213.10M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $382.33M | -36.4% |
| Q2 FY2026 | Jun 30, 2026 | $412.47M | -34.0% |
| Q1 FY2026 | Mar 31, 2026 | $433.53M | -31.4% |
| Q4 FY2025 | Dec 31, 2025 | $488.95M | -25.5% |
| Q3 FY2025 | Sep 30, 2025 | $601.14M | -6.8% |
| Q2 FY2025 | Jun 30, 2025 | $624.75M | -4.1% |
| Q1 FY2025 | Mar 31, 2025 | $631.94M | -3.2% |
| Q4 FY2024 | Dec 31, 2024 | $656.20M | +1.2% |
| Q3 FY2024 | Sep 30, 2024 | $645.12M | +0.5% |
| Q2 FY2024 | Jun 30, 2024 | $651.37M | +1.5% |
| Q1 FY2024 | Mar 31, 2024 | $652.68M | +1.3% |
| Q4 FY2023 | Dec 31, 2023 | $648.44M | +2.2% |
| Q3 FY2023 | Sep 30, 2023 | $641.61M | +3.2% |
| Q2 FY2023 | Jun 30, 2023 | $641.68M | +5.3% |
| Q1 FY2023 | Mar 31, 2023 | $644.53M | +6.8% |
| Q4 FY2022 | Dec 31, 2022 | $634.25M | +6.8% |
| Q3 FY2022 | Sep 30, 2022 | $621.79M | +7.2% |
| Q2 FY2022 | Jun 30, 2022 | $609.10M | +7.3% |
| Q1 FY2022 | Mar 31, 2022 | $603.56M | +11.1% |
| Q4 FY2021 | Dec 31, 2021 | $593.79M | +11.3% |
| Q3 FY2021 | Sep 30, 2021 | $579.77M | +12.4% |
| Q2 FY2021 | Jun 30, 2021 | $567.65M | +12.0% |
| Q1 FY2021 | Mar 31, 2021 | $543.19M | +11.2% |
| Q4 FY2020 | Dec 31, 2020 | $533.46M | +10.3% |
| Q3 FY2020 | Sep 30, 2020 | $515.91M | +8.7% |
| Q2 FY2020 | Jun 30, 2020 | $506.63M | +36.0% |
| Q1 FY2020 | Mar 31, 2020 | $488.53M | +39.1% |
| Q4 FY2019 | Dec 31, 2019 | $483.75M | +45.7% |
| Q3 FY2019 | Sep 30, 2019 | $474.45M | +52.1% |
| Q2 FY2019 | Jun 30, 2019 | $372.48M | +23.0% |
| Q1 FY2019 | Mar 31, 2019 | $351.17M | +10.7% |
| Q4 FY2018 | Dec 31, 2018 | $332.13M | +61.7% |
| Q3 FY2018 | Sep 30, 2018 | $311.94M | +51.6% |
| Q2 FY2018 | Jun 30, 2018 | $302.93M | +43.8% |
| Q1 FY2018 | Mar 31, 2018 | $317.32M | +55.0% |
| Q4 FY2017 | Dec 31, 2017 | $205.43M | -2.4% |
| Q3 FY2017 | Sep 30, 2017 | $205.71M | – |
| Q2 FY2017 | Jun 30, 2017 | $210.67M | – |
| Q1 FY2017 | Mar 31, 2017 | $204.72M | – |
| Q4 FY2016 | Dec 31, 2016 | $210.37M | – |
See a number that looks wrong?